Topics:
Hematologic Malignancies • Medical Oncology • Bone Marrow Transplant • Hematology • Infectious Disease
When are you recommending bone marrow transplant recipients receive the SARS-CoV-2 vaccine?
Does your recommendation differ between autologous and allogeneic transplants?
Does your recommendation differ in allogeneic transplant recipients who have developed acute and/or chronic graft versus host disease (GVHD)?
Answer from: at Academic Institution
The CIBMTR and EBMT data indicate a 20-30% mortality in transplant patients. Risk factors are age >50, male, and <12 months from HSCT. Unfortunately, the complexity of immunological recovery after transplant makes inferring the likelihood of response to a new vaccine formulation impossible. In...
Sign in or Register to read more
Answer from: at Community Practice
Our current practice is to offer the COVID-19 vaccine to our transplant patients 3 months after auto and allo SCT or 6 weeks prior to auto SCT. I agree with Dr. @Joseph H. Antin, we don't have much data yet.
https://www.myast.org/sites/default/files/2021%2001%2025%20COVID19%20VACCINE%20FAQS_update%...